Dewi Vernerey is a research engineer in epidemiology and biostatistics who received a master’s degree cum laude from Joseph Fourier University (Grenoble, France) with a major in  engineering statistics. He defended a PhD in epidemiology and statistics in 2016. His PhD research focused on statistical methodology for risk prediction and prognostic score construction in oncology and kidney transplantation.

    After working for 10 years in Paris at Gustave Roussy institute, Sanofi-Aventis, INSERM Unit 535 and Necker Hospital, he passed in 2009 the national health and medical research institute (INSERM) competitive examination for a research engineer permanent contract.  

    Then, he worked in an epidemiology unit at the Cardiovascular Research Center of Paris (PARCC) located in Georges Pompidou European hospital. In 2013, he decided to join the  Methodology and quality of life unit in Oncology (UMQVC) at the University hospital of Besancon with his engineer permanent contract. He teaches statistics, data Analysis and methodology in master’s degree and in medical school. 

    Since 2017, he is the head of the “Epidemilogy and Biostatistics” UMQVC’s module and the head of the GERCOR statistical team (INCAS’s labelled data center). He is also a member of the ARCAD foundation and of the HaliodDx’s Scientific Advisory Boards.


Research thematic:

  • Methodology in prognostic research and risk stratification
  • Development and improvement of prognostic and/or predictive tools at population and individual level. 

Main areas of expertise:  

  • Statistics and epidemiology
  • Clinical trial design ans analysis
  • Clinical research
  • Genetic epidemiology (linkage and association analyses)
  • Oncology
  • Solid transplantation (kidney and heart)
  • Cardiology

Main ongoing external collaborations :

  • GERCOR (Multidisciplinary Group in Oncology)
  • Fondation ARCAD (Aide et Recherche en Cancérologie Digestive)
  • AGEO (Association des Gastro-Entérologues Oncologues)
  • FRENCH (Fédération de Recherche EN Chirurgie)

Tools online

  • Prognostic Score and Nomogram to Predict Overall Survival in Locally Advanced Pancreatic Cancer: The PROLAP score 
  • Prognostic Nomogram and Score to Predict Overall Survival in Second Line Chemotherapy for Advanced Pancreatic Cancer: The PROSCAP score 

Principaux articles

sample

BACKGROUND:Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : New England Journal of Medicine

sample

AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JCO

sample

AbstractOBJECTIVES:To assess the long term outcomes of transplantation using expanded criteria donors (ECD; donors aged...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMJ

sample

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

sample

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Angélique VIENOT, Mme. Aurélia MEURISSE
Nom de la revue : JNCI J Natl Cancer Inst

Derniers articles

sample

AbstractCirculating cell-free DNA (cfDNA) contains circulating tumor DNA (ctDNA), which can be obtained from serial...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Mol Oncol .

sample

AbstractBackground: Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5-fluorouracil...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Oncologist

sample

AbstractBACKGROUND:At time of diagnosis, less than 10% of patients with pancreatic adenocarcinomas (PDAC) are considered...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

sample

AbstractThe diagnosis system for allograft loss lacks accurate individual risk stratification on the basis of...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : J Am Soc Nephrol

sample

AbstractBACKGROUND:We explored and validated the association of postoperative carcinoembryonic antigen (CEA) with...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Cancer Epidemiol Biomarkers Prev

sample

AbstractBackground: The variability of definitions for time-to-event (TTE) end-points impacts the conclusions of...

Posté par : Mme. Julie HENRIQUES, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

sample

AbstractAnti-EGFR efficacy in patients with microsatellite instability (MSI) metastatic colorectal cancer (mCRC)...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : J Natl Cancer Inst

sample

AbstractBackground: Failed kidney transplant is becoming a frequent cause of dialysis initiation. Although studies...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Nephrol Dial Transplant

sample

AbstractIn metastatic pancreatic adenocarcinoma, a high neutrophil-to-lymphocyte ratio (NLR) at diagnosis is a marker of...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Clin Res Hepatol Gastroenterol

sample

AbstractBACKGROUND:The benefit of second-line chemotherapy (L2) over standard first-line (L1) gemcitabine plus cisplatin...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Eur J Cancer.

Dernières actualités

Derniers outils

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posté par : , Dr. Dewi VERNEREY, , Pr. Franck BONNETAIN,

The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better discrimination for...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY

Currently, the management of advanced pancreatic cancer patients is complex in second-line chemotherapy according to the...

Posté par : Dr. Angélique VIENOT, Dr. Dewi VERNEREY

2015-2021 © Copyright - UMQVC.org

Website by Pearlweb